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If melatonin or its analogs are to be used therapeutically in humans, their chronic effects on responsiveness of melatonin target cells need
to be assessed. We have previously demonstrated that acute melatonin treatment regulates the somatostatinergic system in the rat
hippocampus. In the present study, we have investigated the effects of subchronic and chronic daily treatment with melatonin on the
somatostatinergic system in the rat hippocampus. Male Wistar rats (200–250 g) were injected with melatonin (25 Ag/kg body weight,
subcutaneously) daily for 4, 7 or 14 days and sacrificed 24 h after the last injection. Melatonin administration for 4 days induced a decrease in
the hippocampal somatostatin (SRIF)-like immunoreactivity content as well as a decrease in the number of SRIF receptors and an increase in
their apparent affinity. The decreased number of SRIF receptors in the melatonin (4 days)-treated rats was associated with a decreased
capacity of SRIF to inhibit both basal and forskolin-stimulated adenylyl cyclase activity. These melatonin-induced effects reversed to control
values after 7 or 14 days of treatment. Hippocampal membranes from control and melatonin-treated rats showed similar Gi and Gs activities.
Melatonin treatment altered neither the functional Gi activity nor the Gia1 or Gia2 levels at any of the time periods studied. The present
results suggest that chronic exposure to melatonin results in a tolerance of the hippocampus to this hormone.
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1. Introduction melatonin is known to possess free radical scavenging andIn mammals, melatonin (N-acetyl-5-methoxytryptamine)
is mainly produced by the pineal gland [3] and, to some
extent, by other extrapineal tissues such as the retina and
gastrointestinal tract [34]. It is involved in regulating neu-
roendocrine function and acts directly on the biological
clock in the suprachiasmatic nucleus to modulate the circa-
dian rhytmicity of diverse biological functions such as sleep,
hormonal and temperature cycles [42,43]. To date, only the
Mel1a and Mel1b receptors have been detected in mammals
[43]. Some of the responses of melatonin have been
reported to be mediated through GABA-benzodiazepine
receptors in the central nervous system [23]. In addition,0169-328X/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.molbrainres.2004.03.010
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E-mail address: carmen.boyano@uah.es (E. Arilla-Ferreiro).antioxidant properties [35]. There is increasing interest in
the clinical applications of melatonin as therapeutic agents
in humans [4]. If melatonin or its analogs are to be used
therapeutically in humans, the effects of chronic exposure to
these antagonists on the responsiveness of melatonin target
cells need to be assessed. However, the functional conse-
quence of chronic melatonin treatment has received little
attention, and it is unknown whether such a treatment can
subsequently alter the sensitivity of different brain areas to
melatonin. Previous studies carried out by our group have
demonstrated that acute melatonin treatment regulates the
rat hippocampal somatostatinergic system in vivo [19]. In
the present study, we have investigated the effects of
subchronic and chronic daily melatonin administration on
somatostatin (SRIF)-like immunoreactivity (SRIF-LI) levels
and on [125I]-Tyr11-SRIF binding to its specific receptors in
the rat hippocampus. We have also evaluated the effect of
melatonin on SRIF-mediated inhibition of adenylyl cyclase
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catalytic subunit was measured by stimulating the enzyme
with the diterpene forskolin. The functional activity of Gi
proteins was also determined.2. Materials and methods
2.1. Chemicals and reagents
Melatonin, phenylmethylsulfonyl fluoride (PMSF), 3-
isobutyl-1-methylxanthine (IBMX), bovine serum albumin
(fraction V) (BSA), guanosine triphosphate (GTP), forsko-
lin, pre-stained protein markers and other reagents for
sodium dodecylsulfate-polyacrylamide gel electrophoresis
(SDS/PAGE) were purchased from Sigma (Madrid, Spain).
Specific antiserum against ai1 (MAB3075) or ai2
(MAB3077) G protein subunits was obtained from Chem-
icon International (California, USA). Nitrocellulose mem-
branes as well as the chemiluminescence Western blotting
detection system were purchased from Amersham (Buck-
inghamshire, UK). All other reagents were of the highest
purity commercially available.
2.2. Experimental animals
All procedures regarding handling and treatment of
laboratory animals were carried out in accordance to the
guidelines established by our Animal Care and Use
Committee and were approved by the mentioned Com-
mittee before implementation. Efforts were made to min-
imize animal’s suffering and to use only the exact number
of animals necessary to secure reliable scientific data. In
the present study, male Wistar rats weighing 200–250 g
were used. All animals received food and tap water ad
libitum. Room temperature was kept constant at 22 jC
and 12-h day–night cycles were maintained. Melatonin
was dissolved in saline containing ethanol (0.5%) and
administered subcutaneously (s.c.) at 0900 h in a volume
of 100 Al according to the method described by Alexiuk
and Vriend [2] at a dose of 25 Ag/kg [1] daily for 4, 7 or
14 days. Control animals selected for each experimental
group were injected with saline containing ethanol. All
animals were sacrificed by decapitation 24 h after the last
injection. The brains were removed and the hippocampus
was immediately dissected as described by Glowinski and
Iversen [14].
2.3. Binding assay
Tyr11-SRIF was radioiodinated by chloramine-T iodin-
ation according to the method of Greenwood et al. [15]. The
tracer was purified in a Sephadex G-25 fine column
(1100 cm) equilibrated with 0.1 M acetic acid containing
BSA 0.1% (w/v). The specific activity of the purified
labelled peptide was about 600 Ci/g.Hippocampal membranes were prepared as previously
described by Reubi et al. [36]. Protein concentration was
assayed by the method of Lowry et al. [25], with BSA as a
standard. Specific SRIF binding was measured according to
the modified method of Czernik and Petrack [7]. Briefly, the
membranes (0.15 mg protein/ml) were incubated in 250 Al of
a medium containing 50 mM Tris/HCl buffer (pH 7.5), 5
mM MgCl2, 0.2% (w/v) BSA and 0.1 mg/ml bacitracin with
250 pM [125I]-Tyr11-SRIF either in the absence or presence
of 0.01–10 nM unlabelled SRIF. After a 60-min incubation
at 30 jC, bound and free ligand were separated by centri-
fugation at 11,000 g for 2 min. The supernatant was
discarded and the pellet was washed with Tris (50 mM)–
sacarose (0.9%) buffer (pH 7.4). The radioactivity in the
pellet was measured in a Kontron gamma counter. Nonspe-
cific binding was obtained from the amount of radioactivity
bound in the presence of 10 7 M SRIF and represented
about 20% of the binding observed in the absence of
unlabelled peptide. This nonspecific component was sub-
tracted from the total bound radioactivity in order to obtain
the corresponding specific binding.
2.4. Evaluation of radiolabelled peptide degradation
The inactivation of [125I]-Tyr11-SRIF in the incubation
medium after exposure to membranes was studied by
measuring the ability of preincubated peptide to rebind to
fresh membranes. Briefly, [125I]-Tyr11-SRIF (250 pM) was
incubated with membranes from rat hippocampus (0.15 mg
protein/ml) for 60 min at 30 jC. After this preincubation,
aliquots of the medium were added to fresh membranes and
incubated for an additional 60 min at 30 jC. The fraction of
the added radiolabelled peptide which was specifically
bound during the second incubation was measured and
expressed as a percentage of the binding that had been
obtained in control experiments performed in the absence of
membranes during the preincubation period.
2.5. Tissue extraction and somatostatin radioimmunoassay
For measurements of SRIF-LI content, the hippocampus
was rapidly homogenized in 1 ml of 2 M acetic acid using a
Brinkman polytron (setting 5, 30 s). Extracts were boiled for
5 min in a water bath and chilled on ice. Subsequently,
homogenates were centrifuged at 15,000 g for 15 min at 4
jC. The pellet was discarded and 25 Al of the supernatant
were taken for protein analysis [25]. Extracts were imme-
diately stored at  80 jC until assay. The immunoreactivity
content was determined in tissue extracts by a modified
radioimmunoassay method [31], with a sensitivity limit of
10 pg/ml. The possibility that substances present in the
tissue extracts might interfere with antibody–antigen bind-
ing and give rise to erroneous results was checked by
performing serial dilutions of selected extracts in the assays
and comparing the resulting changes in SRIF-LI with those
of the diluted standards. In addition, known standard
Table 1
Effect of melatonin at a daily dose of 25 Ag/kg s.c. during 4, 7 or 14 days on




Control 543F 12 0.51F 0.04
Melatonin 4 days 399F 23*** 0.35F 0.04*
Control 478F 9 0.48F 0.02
Melatonin 7 days 456F 12 0.52F 0.03
Control 488F 10 0.40F 0.02
Melatonin 14 days 476F 30 0.39F 0.01
Binding parameters were calculated from Scatchard plots by linear
regression. Units for Kd are nM, units for Bmax are fmol of SRIF bound
per mg of protein. The results are represented as the meanF S.E.M. of five
separate experiments, each performed in duplicate. Statistical comparison
versus control: *p< 0.05; ***p< 0.001.
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the extracts and serial dilutions were again assayed, in order
to determine if this exogenously added hormonal immuno-
reactivity could be measured reliably in the presence of
tissue extracts. Incubation tubes prepared in duplicate
contained 100 Al samples of unknown or standard solutions
of 0–500 pg cyclic SRIF tetradecapeptide, diluted in
phosphate buffer (0.1 M, pH 7.2 containing 0.2% BSA,
0.1% sodium azide), 200 Al of appropriately diluted anti-
SRIF serum, 100 Al of freshly prepared [125I]-Tyr11-SRIF,
diluted in buffer to yield 6000–10000 cpm (equivalent to
5–10 pg), and enough buffer to give a final volume of 0.8
ml. All reagents, as well as the assay tubes, were kept
chilled in ice before incubation at 4 jC for 24 h. Separation
of bound and free hormone was accomplished by addition
of 1 ml dextran-coated charcoal (dextran: 0.2% w/v).
Dilution curves for each brain area were parallel to the
standard curve. The coefficients for intra- and inter-assay
variation were 6.5% and 8.3%, respectively.
2.6. Adenylyl cyclase assay
Hippocampal membranes were prepared as previously
described by Reubi et al. [36]. Protein concentration was
assayed by the method of Lowry et al. [25] with BSA as a
standard. AC activity was measured as previously described
[18], with some minor modifications. Briefly, hippocampal
membranes (0.06 mg/ml) were incubated with 1.5 mM ATP,
5 mM MgSO4, 10 AM GTP, an ATP-regenerating system
(7.5 mg/ml creatine phosphate and 1 mg/ml creatine kinase),
1 mM IBMX, 0.1 mM PMSF, 1 mg/ml bacitracin, 1 mM
EDTA, and test substances (10 4 M SRIF or 10 5 M
forskolin) in 0.1 ml of 0.025 M triethanolamine/HCl buffer
(pH 7.4). After a 15-min incubation at 30 jC, the reaction
was stopped by heating the mixture at 100 jC for 3 min.
Once cooled, 0.2 ml of an aluminum slurry (0.75 g/ml in
triethanolamine/HCl buffer, pH 7.4) was added and the
suspension was centrifuged. The supernatant was then
removed for assay of cyclic AMP (cAMP) by the method
described by Gilman [12]. The SRIF concentration used was
that deemed necessary to achieve inhibition of rat [39] AC
activity. Similarly, forskolin was used at a concentration that
could effectively stimulate the catalytic subunit of rat AC
[39].
2.7. Immunodetection of G protein ai subunits
Membranes (100 Ag) were solubilized in SDS-sample
buffer and the resulting proteins were then run on a 12%
SDS-polyacrylamide gel as described by Laemmli [21].
After separation, the proteins were transferred onto nitro-
cellulose membranes in a buffer consisting of 25 mM Tris/
HCl, pH 8.3, 192 mM glycine, 20% methanol and 0.05%
SDS. The transferred nitrocellulose membranes were
blocked with TTBS (50 mM Tris/HCl, pH 7.5, 150 mM
NaCl, and 0.05% Tween-20) containing 5% (w/v) non-fatdry milk during 1.5 h at 4 jC. Nitrocellulose membranes
were subsequently immunoblotted with anti-Gia1 or anti-
Gia2 monoclonal antibodies (1:1000 dilution) in TTBS and
incubated overnight at 4 jC. After incubation, three 5-min
washes in TTBS containing 5% (w/v) non-fat dry milk were
carried out. A mouse IgG–peroxidase conjugate (1:2000
dilution) in TTBS was then added to the membranes and
incubated for 1 h at 4 jC. After washing, the bound
immunoreactive proteins were detected by a chemilumines-
cent (ECL) Western blotting detection system.
2.8. Data analysis
Statistical comparisons of all the data were carried out by
one-way analysis of variance (ANOVA) and the Student–
Newman–Keuls test. Means among groups were considered
significantly different when the p values were less than 0.05.
Each experiment was performed in duplicate.3. Results
Preliminary experiments confirmed that the specific
binding of [125I]-Tyr11-SRIF to hippocampal membranes
changed linearly with protein concentration and was time-
dependent in all experimental groups. An apparent equilib-
rium was observed between 50 and 180 min at 30 jC (data
not shown). All subsequent binding experiments were there-
fore conducted at 30 jC for 60 min. Our group [20] has
studied the specific binding of [125I]-Tyr11-SRIF to hippo-
campal membranes in rats treated with 10, 25, 50 or 100 Ag/
kg, s.c., of melatonin. The doses of 10 and 25 Ag/kg
significantly decreased the specific binding of [125I]-Tyr11-
SRIF to rat hippocampal membranes as compared to the
control group, with no changes being observed at the higher
doses. Since the maximal effect of melatonin on SRIF
receptors was detected at the dose of 25 Ag/kg, subsequent
studies were carried out at this dose. Stoichiometric experi-
ments were performed on rat hippocampal membranes using
Fig. 1. Scatchard plots of the specific binding of [125I]-Tyr11-SRIF to rat hippocampal membranes. Membranes (0.15 mg of protein/ml) were incubated for 60
min at 30 jC in the presence of 250 pM [125I]-Tyr11-SRIF and increasing concentrations of SRIF. Points correspond to control rats (o), and rats treated with
melatonin for 4 days (.) (A), 7 days (E) (B) and 14 days (z) (C). The animals were sacrificed 24 h after the last injection.
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doses of unlabelled SRIF at 30 jC for 60 min. Melatonin
administration during 4 days produced a significant decrease
in [125I]-Tyr11-SRIF binding to rat hippocampal membranes
as compared to controls. This decrease was due to a decrease
in the maximal number of SRIF receptors as revealed by
Scatchard plots of the binding data (Table 1; Fig. 1). In
addition, a significant increase in the affinity of these
receptors was observed (Table 1; Fig. 1). No changes in
the SRIF receptor number or affinity were observed, how-
ever, at 7 or 14 days of melatonin administration (Table 1).
Daily melatonin administration for 4 days decreased
SRIF-LI content in the rat hippocampus as compared
with the control group (Fig. 2). No changes wereFig. 2. Effect of melatonin (25 Ag/kg) treatment for 4, 7 or 14 days on
somatostatin (SRIF)-like immunoreactivity in the rat hippocampus. Values
are expressed as the meanF S.E.M. of five experiments, each performed in
duplicate. Statistical comparison versus control: *p< 0.05.observed after 7 or 14 days of melatonin administration
(Fig. 2).
One of the signalling pathways coupled to SRIF recep-
tors is the inhibition of AC. Therefore, in order to investi-
gate whether the functional effect of SRIF was affected by
melatonin treatment, hippocampal membranes from control
and melatonin-treated rats were assayed for SRIF-induced
inhibition of AC activity. In the melatonin-treated groups,
the degree of SRIF inhibition of both basal and forskolin-
stimulated AC activity was significantly lower than in the
control group after 4 days of its daily administration (Table
2). After 7 or 14 days of melatonin treatment, no significant
differences were observed in this parameter (data not
shown).
To test if the observed changes were related to modifi-
cations in the expression of AC, the response of the enzyme
to the diterpene forskolin (10 5 M), which is assumed to act
directly upon the catalytic subunit, was measured. No
significant differences were detected in the fold forskolin
stimulation over basal AC activity between the control
group and melatonin-treated rats (Table 2).
Further experiments were carried out to explore the effect
of melatonin on the functionality of Gi or Gs proteins inTable 2
Effect of somatostatin (SRIF) (10 4 M) and forskolin (FK) (10 5 M) on
brain adenylyl cyclase activity (pmol cAMP/min/mg protein) in hippo-
campal membranes from control and melatonin (25 Ag/kg, s.c.)-treated rats
for 4 days
Control Melatonin
Basal activity 234.8F 4.2 263.0F 5.9
+ 10 4 M SRIF 191.5F 4.3 236.6F 6.2
+ 10 5 M FK 638.6F 4.2 634.7F 10.9
+ 10 5 M FK+ 10 4 M SRIF 515.0F 17.1 574.4F 12.2
Fold FK stimulation over basal 2.7F 0.12 2.4F 0.08
%SRIF inhibition of basal activity 18.4F 1.7 10.0F 1.8**
%SRIF inhibition of FK stimulation 18.8F 3.7 9.5F 0.6*
Values represent the meanF S.E.M. of five separate experiments, each
performed in duplicate. Statistical comparison versus control: *p< 0.05;
**p< 0.01.
Fig. 3. Dose–effect curves for 5-guanylylimidodiphosphate [Gpp(NH)p]-
mediated inhibition of adenylyl cyclase activity in rat hippocampal
membranes from control (o, n= 5) and melatonin (25 Ag/kg)-treated (.,
n= 5) rats. The effect of Gpp(NH)p on adenylyl cyclase activity was studied
in the presence of 3 10 6 M forskolin and the indicated concentrations of
Gpp(NH)p. Data are expressed as a percentage of forskolin-stimulated
adenylyl cyclase activity in the absence of Gpp(NH)p (100%). The results
are given as the meanF S.E.M. of five separate determinations, each
performed in duplicate.
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low and high Gpp(NH)p concentrations to inhibit forskolin
(3 10 6 M)-stimulated AC activity. Characteristic bi-
phasic response curves were obtained in all the experimental
groups. Gpp(NH)p concentrations ranging from 10 11 to
10 7 M decreased AC activity due to Gi activation, whereas
higher nucleotide concentrations (10 6–10 4 M) resulted
in stimulation of both AC and Gs activities. Hippocampal
membranes from control and melatonin-treated rats showed
similar functional activity Gi and Gs (Fig. 3).
In order to investigate whether the levels of the inhibitory
G protein (Gia1 and Gia2) were affected by melatonin,
Western blot analyses were performed. Melatonin adminis-
tration for 4, 7 or 14 days did not significantly alter the
amount of the Gia1 or Gia2 subunits in hippocampal
membranes (data not shown).4. Discussion
The present study has examined the effects of short- and
long-term melatonin (25 Ag/kg, s.c.) administration on the
rat hippocampal somatostatinergic system. Previous studies
have shown that subcutaneous melatonin injection results in
a rapid increase in the serum levels of this indol 30 min after
its administration [26] and a gradual reduction in these
levels 90 or 180 min later. Circulating melatonin passes
the blood barrier and binds to its receptors, as demonstratedby systemic injection of radioactive melatonin in rodents
[13,44]. A minimal dose of melatonin such as 25 Ag/kg
body weight during 4 days was enough to decrease both the
SRIF-LI content in the rat hippocampus and the specific
binding of [125I]-Tyr11-SRIF to rat hippocampal membranes
as compared to the control group. The SRIF-LI content and
equilibrium parameters of the SRIF receptors in the hippo-
campus of control rats were similar to those previously
reported by others [32,41].
Some of the responses induced by melatonin have been
reported to be mediated via GABA-benzodiazepine recep-
tors in the CNS [24,29,38,45]. Previous results from our
group [19] suggest that melatonin via interaction with
GABA receptors could modulate the rat hippocampal SRI-
Fergic system. Thus, since melatonin inhibits GABA recep-
tor function in the rat hippocampus [10] and GABA
antagonists have been found to stimulate SRIF release
[37], melatonin may lead to an increase in SRIF release
and, therefore, to a decrease in SRIF content in the hippo-
campus as seen at 4 days of daily melatonin administration.
An increased SRIF release might lead to a decrease in the
density of the SRIF receptors in adjacent SRIF-containing
neurons. Thus, regulation of SRIF receptors by SRIF
appears to be similar to that of other hormone–receptor
systems [8,22].
Basal and forskolin-stimulated AC activity was inhibited
by SRIF in all the experimental groups studied, which is in
agreement with the literature [27]. A high concentration of
SRIF (10 4 M) was required to produce this inhibition
although the same concentration was used by other
researchers in their studies on SRIF-mediated inhibition of
AC activity in rat brain [11,28]. In a previous study from our
group, the inhibitory effect of increasing SRIF concentra-
tions on basal and forskolin (10 5 M)-stimulated AC
activity in control rats was analyzed [33]. SRIF-mediated
inhibition of AC activity was only significant at the max-
imal concentration tested (10 4 M). Thus, this concentra-
tion was chosen for subsequent studies on AC activity. It
should also be noted that abundant studies on the SRIF
effect on AC activity were performed in cell lines express-
ing higher levels of SRIF receptors than in animal tissues.
This may be due to the cell heterogeneity of the present
preparations. Thus, SRIF inhibited basal AC activity in
neuronal but not glial cells [5,6]. On the other hand, the
synaptic concentration of SRIF is, to date, unknown. How-
ever, it is tempting to speculate that because the hippocam-
pus is very rich in SRIF-containing neurons, the amount of
SRIF released may be sufficiently great as to justify the high
SRIF concentration used to inhibit AC activity. Therefore, it
is possible that this concentration of SRIF is necessary to
inhibit AC activity in our experimental conditions.
Melatonin administration led to a decrease in SRIF-
mediated inhibition of basal and forskolin-stimulated AC
activity after a short-term 4-day daily administration. How-
ever, no changes were detected in either the basal or
forskolin-stimulated AC activity, suggesting that the de-
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an alteration of the AC catalytic subunit. Gi protein func-
tionality, as measured by the capacity of Gpp(NH)p to
inhibit forskolin-stimulated AC activity, was similar in both
the melatonin-treated and control rats. On the other hand,
Western blots of the Gia1 or Gia2 proteins indicate that
neither protein was modified by melatonin. Taken together,
the present results suggest that the decrease in SRIF-medi-
ated inhibition of AC activity is most probably due to the
decrease in the number of SRIF receptors.
The melatonin-induced changes in the hippocampal
SRIFergic system reversed to control values after 7 or 14
days of daily administration. This finding is in agreement
with studies from Hadley [16], who demonstrated that
continuous exposure to melatonin renders the target tissue
unresponsive to the hormone. It has previously been
reported that the total number of melatonin receptors in
the hippocampal midbrain [30] and pars tuberalis of the
anterior pituitary [17] may be reduced following prolonged
exposure to melatonin.
Recently, Li et al. [24] have described that melatonin
induces desensitization of the GABAA receptor. Several
experiments indicate that there is a binding site for melato-
nin on the GABAA receptor [29,38]. Allosteric modulation
of GABA receptors by melatonin was demonstrated in the
rat brain [29]. This allosteric modulation provides a possible
mechanism for regulating GABAergic transmission leading
to desensitization of GABA receptors. Therefore, it is
possible that a continuous exposure to melatonin via
GABAA receptor desensitization causes the SRIF system
to return to control values. In this regard, it should be noted
that there are GABAA receptors located in hippocampal
SRIF-containing neurons [9,10] so that desensitization of
GABAA receptors could blunt the release of SRIF which
could explain the return of SRIF levels and SRIF receptors
to control values.
The significance of the changes in the SRIF receptor–
effector system induced by melatonin remains to be estab-
lished. However, the fact that acute melatonin administra-
tion leads to a memory deficit is in agreement with the
decrease of the SRIFergic system, which increases memory
processes. In addition, the fact that memory deficits induced
by melatonin revert to control values after chronic treatment
with melatonin during 7 days [40] correlates with the return
of activity to control values, as shown in this study.
Therefore, the present results suggest that chronic exposure
to melatonin results in tolerance of the rat hippocampus to
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